Home
»
Press Room
»
Vaginitis Therapeutics Market To Reach $6.10Bn By 2030

Vaginitis Therapeutics Market To Reach $6.10 Billion By 2030

January 2025 | Report Format: Electronic (PDF)

Vaginitis Therapeutics Market Growth & Trends

The global vaginitis therapeutics market size is expected to reach USD 6.10 billion by 2030, registering a CAGR of 7.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Supportive initiatives by government and non-government agencies to increase awareness level among women is driving the demand for vaginitis drugs. Increased consumption of alcohol is also estimated to fuel the adoption of these drugs. Around 5.3 million women in the U.S. are at risk related to health and general well-being.

Furthermore, rising R&D activities for vaginitis therapeutics is anticipated to accelerate the market growth. National Institute of Allergy and Infectious Diseases (NIAID)-funded research has discovered various important data about yeast generative behavior, which could result in new way of treatment for yeast infections. In addition, introduction of new drugs by key companies is expected to propel the market growth. For instance, in September 2017, Symbiomix Therapeutics received FDA approval for Solosec (secnidazole) for the treatment of bacterial vaginosis.

Request a free sample copy or view report summary: Vaginitis Therapeutics Market Report

Vaginitis Therapeutics Market Report Highlights

Anti-bacterial diseases led the market and accounted for a share of 37.1% in 2023. A 2021 study in Infection and Drug Resistance reports that bacterial vaginosis (BV) affects approximately 29.2% of women of reproductive age globally.
Prescription therapeutics dominated the market and accounted for a share of 51.6% in 2023. The demand for prescription medications to treat severe and recurrent vaginitis is driven by their higher efficacy and safety.
Retail pharmacies held the largest revenue share of 48.5% in 2023, owing to convenience, wide product range, and growing awareness of women’s health issues.
North America vaginitis therapeutics market dominated the global market with a revenue share of 37.7% in 2023, owing to its well-established healthcare infrastructure, high healthcare spending, and strong R&D focus.
Asia Pacific vaginitis therapeutics market is expected to register the fastest CAGR of 8.6% over the forecast period, driven by improving healthcare access and increasing awareness of women’s health issues.